DIRECTOR'S OVERVIEW AND ESSENTIAL CHARACTERISTICS ABSTRACT The Oregon Health & Science University (OHSU) Knight Cancer Institute (the Knight) is a matrix cancer center at OHSU in Portland, Oregon. The goal of the Knight is to perform cancer-focused research and to convert these findings into treatments and prevention strategies to improve outcomes for cancer patients. The OHSU Knight Cancer Institute has 139 members who belong to four scientific programs - Cancer Biology, Translational Oncology, Quantitative Oncology, and Cancer Prevention and Control and utilize six well-established shared resources - Flow Cytometry, Proteomics, Advanced Multiscale Microscopy, Integrated Genomics, BioLibrary & Pathology, and Biostatistics. The 139 Knight members are supported by $87.6 million in total extramural funding, $42.9 million of which is from the NCI. In the current funding period, members have published 1,139 cancer focused, peer-reviewed publications, of which 24% were intra-programmatic, 15% inter-programmatic, and 62% externally collaborative. In 2015 a total of 481 patients were enrolled on therapeutic treatment trials, representing over 10% of our new patient population. OHSU is the only academic medical center in Oregon and the Knight Cancer Institute is the only NCI-designated cancer center in the state. The Knight's catchment area is defined as the entire state of Oregon. Our research efforts are targeted to populations and cancers that are unique to our catchment area and includes evaluating populations in our catchment area that are more likely to diagnosed with late-stage cancers. Serving as the advanced oncology care facility for the state, the Knight brings depth and breadth to basic laboratory research; clinical research, including early phase clinical trials; and prevention, control, and population-based research with training programs for cancer researchers and health care professionals. In the current funding period we have recruited 32 new investigators, including four Associate Directors, completely restructured the leadership committees and the programmatic structure of the Knight to facilitate intra- and inter-programmatic interactions and to accelerate progress in achieving our goals. This has led to a significant increase in cancer focus, an increase in NCI funding, and enhanced collaborations as demonstrated by publications and collaborative grants. Given our growth and accomplishments in the current funding period, we request consideration for continued funding and feel we are well positioned for consideration of comprehensive status.
DIRECTOR'S OVERVIEW AND ESSENTIAL CHARACTERISTICS PROGRAM NARRATIVE The OHSU Knight Cancer Institute has made numerous impactful contributions since its designation as one of the nation's National Cancer Institute Cancer Centers in 1997. This has included establishing the paradigm of targeted cancer therapy, now referred to as precision medicine. Through the work supported by our Cancer Center Support Grant, we conduct cancer research that spans basic, clinical and prevention and control research that aims to improve outcomes for cancer patients in our catchment area and throughout the nation.
|Farrell, Amy S; Joly, Meghan Morrison; Allen-Petersen, Brittany L et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun 8:1728|
|De Maria, Alicia; Wilmarth, Phillip A; David, Larry L et al. (2017) Proteomic Analysis of the Bovine and Human Ciliary Zonule. Invest Ophthalmol Vis Sci 58:573-585|
|Danelishvili, Lia; Chinison, Jessica J J; Pham, Tuan et al. (2017) The Voltage-Dependent Anion Channels (VDAC) of Mycobacterium avium phagosome are associated with bacterial survival and lipid export in macrophages. Sci Rep 7:7007|
|Avenarius, Matthew R; Krey, Jocelyn F; Dumont, Rachel A et al. (2017) Heterodimeric capping protein is required for stereocilia length and width regulation. J Cell Biol 216:3861-3881|
|Cassidy, Pamela B; Liu, Tong; Florell, Scott R et al. (2017) A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila) 10:36-44|
|Tsujikawa, Takahiro; Kumar, Sushil; Borkar, Rohan N et al. (2017) Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Rep 19:203-217|
|Kwon, Sunjong; Chin, Koei; Nederlof, Michel et al. (2017) Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. Sci Rep 7:16459|
|Midgett, Madeline; López, Claudia S; David, Larry et al. (2017) Increased Hemodynamic Load in Early Embryonic Stages Alters Endocardial to Mesenchymal Transition. Front Physiol 8:56|
|Krey, J F; Wilmarth, P A; David, L L et al. (2017) Analysis of the Proteome of Hair-Cell Stereocilia by Mass Spectrometry. Methods Enzymol 585:329-354|
|Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134|
Showing the most recent 10 out of 248 publications